Clinical Trials

20 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

33 enrolled

Colorectal Neoplasms

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

68 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT05954429 2026-01-22

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

50 enrolled

Colorectal Neoplasms

NCT07353268 2026-01-20

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

76 enrolled

Colorectal Neoplasms

NCT07042685 2026-01-16

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

50 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07229872 2025-11-17

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

18 enrolled

Colorectal Neoplasms

NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

102 enrolled

Metastatic Colorectal Adenocarcinoma

NCT07170982 2025-09-12

Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

128 enrolled

Gynecologic

Endometrial Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Colonic Neoplasms

NCT05941325 2025-05-18

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

20 enrolled

Sarcoma

NCT06791083 2025-01-24

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Stomach Neoplasms

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

66 enrolled

Fruquintinib

NCT06446154 2024-12-31

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

36 enrolled

Carcinoma, Hepatocellular

NCT06706895 2024-11-27

A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer

21 enrolled

Advanced Gastric Cancer

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

46 enrolled

Colorectal Cancer Metastatic

NCT06646588 2024-10-17

SJZ-RMEEC01

67 enrolled

Esophageal Neoplasms

NCT05625737 2024-09-19

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

29 enrolled

Stomach Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT05690035 2024-07-09

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Phase 2 Withdrawn

Colorectal Neoplasms

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT06234007 2024-03-18

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

45 enrolled

Colorectal Neoplasms

NCT05122091 2024-02-26

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

53 enrolled

Stomach Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

39 enrolled

Colorectal Neoplasms

NCT06168786 2023-12-21

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Neoplasms

NCT06091423 2023-11-30

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

43 enrolled

Stomach Neoplasms

NCT06094868 2023-10-23

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

45 enrolled

Stomach Neoplasms

NCT06018714 2023-08-31

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

64 enrolled

Colorectal Neoplasms

NCT05795296 2023-08-30

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

30 enrolled

Stomach Neoplasms

NCT05971199 2023-08-02

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

27 enrolled

Carcinoma, Hepatocellular

NCT05025631 2023-04-28

DOFEMCRC

Phase 2 Completed

29 enrolled

Colorectal Neoplasms

NCT05763927 2023-03-10

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

44 enrolled

Rectal Neoplasms

NCT05643677 2022-12-09

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT05636150 2022-12-05

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05634590 2022-12-02

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT05575635 2022-10-12

Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC

Rectal Neoplasms

NCT05511051 2022-08-22

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

102 enrolled

Colorectal Neoplasms

NCT05004831 2022-08-18

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

54 enrolled

Colorectal Neoplasms

NCT04924179 2022-08-17

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

25 enrolled

Patients With Advanced Metastatic Colorectal Cancer

NCT04733963 2022-07-26

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

112 enrolled

Colorectal Neoplasms

NCT04866862 2022-07-25

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

32 enrolled

Colorectal Neoplasms

NCT05451719 2022-07-12

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

116 enrolled

Colorectal Neoplasms

NCT05447715 2022-07-07

Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

134 enrolled

Colorectal Neoplasms

NCT05406206 2022-06-06

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

27 enrolled

Advanced Colorectal Carcinoma

NCT05292417 2022-03-31

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

71 enrolled

Colorectal Neoplasms

NCT05241899 2022-02-16

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

56 enrolled

Stomach Neoplasms

NCT05168527 2022-01-14

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

30 enrolled

Pancreatic Neoplasms

NCT04582981 2021-10-26

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

136 enrolled